Drug evidence watch: a process to the benefit of public health (2023)
Attributed to:
The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(23)00633-5
PubMed Identifier: 37060913
Publication URI: http://europepmc.org/abstract/MED/37060913
Type: Journal Article/Review
Parent Publication: The Lancet
Issue: 10406